Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elecoglipron for Weight Management in Obesity or Overweight (Embold)
NCT07667803Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2026
- Primary completion
- Jul 2028
- Countries
- 19
01
Overview
A Phase 3 trial of elecoglipron in obesity, sponsored by AstraZeneca. Started Jun 2026; status: recruiting.
02
Drugs
elecoglipron
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07667803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07667803.